Loading financials from SEC filings…
Scientific & technical instruments · Technology · Fiscal year ends Dec 31
Sensata Technologies reported revenue of $3.7B in the fiscal year ended Dec 2025, down 5.8% from the year before. Operating income was $238M, an operating margin of 6.4%, and net income was $31M. Operating cash flow of $622M less capital expenditure of $131M left free cash flow of $490M. Net debt was $2.3B.
Ranks among the 19 scientific & technical instruments companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3,821 | 4,029 | 4,054 | 3,933 | 3,705 |
| Cost of revenue | 2,542 | 2,712 | 2,793 | 2,777 | 2,620 |
| Gross profit | 1,278 | 1,317 | 1,261 | 1,156 | 1,084 |
| Research & development | 159 | 189 | 179 | 169 | 134 |
| Selling, general & admin | 337 | 371 | 351 | 392 | 356 |
| Operating income | 633 | 670 | 182 | 149 | 238 |
| Net interest incomeBanks | −179 | −179 | – | – | – |
| Interest expense | 183 | 196 | 182 | 156 | 149 |
| Pre-tax income | 414 | 397 | 17.8 | −11.8 | 123 |
| Income tax | 50.3 | 86.0 | 21.8 | −140 | 92.0 |
| Net income | 364 | 311 | −3.9 | 129 | 31.3 |
| Diluted EPS | 2.28 | 1.99 | −0.03 | 0.85 | 0.21 |
| Diluted shares | 159 | 156 | 152 | 151 | 147 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 1,709 | 1,226 | 508 | 594 | 573 |
| Receivables | 653 | 742 | 744 | 660 | 657 |
| Inventory | 588 | 645 | 713 | 615 | 618 |
| Current assets | 3,077 | 2,775 | 2,102 | 2,027 | 1,994 |
| Net PP&E | 821 | 841 | 886 | 822 | 777 |
| Goodwill | 3,502 | 3,911 | 3,543 | 3,384 | 3,158 |
| Total assets | 8,614 | 8,756 | 7,681 | 7,143 | 6,752 |
| Payables | 459 | 532 | 482 | 362 | 413 |
| Current liabilities | 836 | 1,179 | 824 | 711 | 775 |
| Short-term debt | 4.6 | 255 | 0.0 | – | – |
| Long-term debt | 4,215 | 3,959 | 3,374 | 3,176 | 2,829 |
| Total liabilities | 5,519 | 5,645 | 4,685 | 4,253 | 3,966 |
| Shareholders' equity | 3,095 | 3,111 | 2,996 | 2,890 | 2,785 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 554 | 461 | 457 | 552 | 622 |
| Capital expenditure | 144 | 150 | 185 | 159 | 131 |
| Free cash flow | 410 | 311 | 272 | 393 | 490 |
| Depreciation & amortisation | 259 | 281 | 307 | 313 | 256 |
| Stock-based compensation | 25.7 | 31.8 | 30.0 | 38.5 | 25.0 |
| Acquisitions | 736 | 632 | 0.0 | 0.0 | – |
| Share buybacks | 47.8 | 292 | 88.4 | 68.9 | 121 |
| Dividends paid | 0.0 | 51.1 | 71.5 | 72.2 | 70.4 |
| Dividend per share | – | 0.33 | – | – | – |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 5.5% | 0.6% | −3.0% | −5.8% |
| Operating income growth (YoY) | – | 5.8% | −72.9% | −17.8% | 59.1% |
| EPS growth (YoY) | – | −12.7% | −101.5% | – | −75.3% |
| Gross margin | 33.5% | 32.7% | 31.1% | 29.4% | 29.3% |
| Operating margin | 16.6% | 16.6% | 4.5% | 3.8% | 6.4% |
| Net margin | 9.5% | 7.7% | −0.1% | 3.3% | 0.8% |
| Return on equityBlank when equity is negative | 11.7% | 10.0% | −0.1% | 4.4% | 1.1% |
| ROCEEBIT ÷ (assets − current liabilities) | 8.1% | 8.8% | 2.6% | 2.3% | 4.0% |
| Free cash flow margin | 10.7% | 7.7% | 6.7% | 10.0% | 13.2% |
| Cash conversion (CFO ÷ net income) | 1.52x | 1.48x | −117x | 4.29x | 19.9x |
| Receivable days | 62 | 67 | 67 | 61 | 65 |
| Inventory days | 84 | 87 | 93 | 81 | 86 |
| Payable days | 66 | 72 | 63 | 48 | 58 |
| Interest cover | 3.47x | 3.43x | 1.00x | 0.96x | 1.59x |
| Debt ÷ equity | 1.36x | 1.35x | 1.13x | 1.10x | 1.02x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | 2,511 | 2,988 | 2,866 | 2,582 | 2,256 |
| Current ratio | 3.68x | 2.35x | 2.55x | 2.85x | 2.57x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.